Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

LBT-3627 is under development for the treatment of Parkinson's disease. The drug candidate is administered through oral route. It is developed based on hybridtide scaffold technology. It acts by ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Elon Musk has dished the secrets behind his recent weight loss transformation.

August 15, 2024, Paper: "Glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists are among the most promising medical innovations of the ...

Abstract and Introduction Prevalence Diagnosing GERD in Asthmatics Management of Reflux-Triggered Asthma References Ravinder P. S. Makkar, MBBS, MD, Medical Advisor, Department of Medical ...

Viking Therapeutics’ VK2735 is a dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors being studied to treat metabolic disorders, including obesity.